CIDP Treatment: First-Line Options and Emerging Therapies

Chronic inflammatory demyelinating polyneuropathy, usually called CIDP, is treated primarily with intravenous immunoglobulin (IVIg), corticosteroids, or plasma exchange, and most people respond to at least one of these first-line options. But CIDP is a chronic condition with highly variable course, and treatment rarely follows a simple script. Choosing the right therapy, adjusting doses over time, and deciding when to attempt withdrawal all involve trade-offs that differ from one person to the next.

First-Line Treatments and How They Compare

International guidelines from the European Academy of Neurology and Peripheral Nerve Society strongly recommend IVIg or corticosteroids as the initial treatment for typical CIDP and its recognized variants, with plasma exchange reserved for people who do not respond to either of those options.¹ An overview of Cochrane systematic reviews found that IVIg produced more short-term improvement than placebo across five trials, and that there was little difference in short-term disability improvement when IVIg was compared head-to-head with either oral prednisolone or intravenous methylprednisolone.² In practical terms, both IVIg and corticosteroids work roughly equally well for many patients, so the choice often comes down to side-effect profiles, cost, and the person’s other health conditions.

IVIg is the most commonly used first-line option, in part because it tends to work quickly and avoids the long-term side effects of steroids. A randomized trial testing three maintenance doses of IVIg found response rates of about 65% at the lowest dose, 80% at the standard dose, and 92% at the highest dose, confirming that dose matters and that many patients can be maintained on a moderate regimen.³ The mechanism involves broad immunomodulatory effects: IVIg appears to dampen the autoimmune attack on peripheral nerves in part by restoring the expression of an inhibitory receptor on immune cells that is underactive in CIDP.⁴

Corticosteroids are the other mainstay. They are far cheaper than IVIg and can be given as pills, which matters when infusion access is limited. High-dose pulsed dexamethasone and daily prednisolone have been directly compared in a randomized trial (the PREDICT study), which found that both produced remission in a meaningful proportion of patients at 12 months, with no significant difference between the two steroid regimens.⁵ In longer follow-up of patients who initially responded to steroids, about a quarter achieved cure or sustained remission lasting more than five years off treatment, though half of those who initially entered remission eventually relapsed.⁶ The downside of corticosteroids is well known: prolonged use carries risks of weight gain, bone thinning, elevated blood sugar, and other systemic effects.

Plasma exchange, in which blood is filtered to remove the antibodies thought to be driving nerve damage, provides significant short-term improvement in disability and nerve conduction. But the effect tends to be temporary: in one trial, most patients who improved after plasma exchange deteriorated again rapidly afterward.⁷ For that reason, plasma exchange is mostly used as a bridge or a rescue strategy rather than a long-term maintenance therapy.

Subcutaneous Immunoglobulin as a Maintenance Alternative

One of the more meaningful practical advances in CIDP treatment has been the development of subcutaneous immunoglobulin (SCIg) as an alternative to the standard intravenous route. The PATH trial, the largest randomized trial in CIDP at the time of its publication, showed that two different doses of subcutaneous immunoglobulin were both effective and well tolerated as maintenance therapy.⁸ The appeal is straightforward: people can infuse themselves at home without needing a vein or premedication, and systemic side effects like headaches and chills are less common than with IVIg. Local injection-site reactions happen more frequently, but these are usually mild and tend to diminish over time.⁹

Longer-term data are encouraging. A follow-up study tracking patients for up to seven years found that strength and motor function remained stable or improved during SCIg maintenance, with benefits in walking ability, hand function, and fatigue. Notably, all 17 patients in that cohort reported improved quality of life, and the vast majority preferred subcutaneous infusions to their previous IVIg regimen.¹⁰ Post-marketing surveillance in Japan confirmed the general safety profile: injection-site redness and swelling were the most frequent complaints, occurring in about a third of patients, but serious reactions were rare.¹¹

When First-Line Treatment Does Not Work

A frustrating reality of CIDP is that a sizable minority of patients do not respond adequately to IVIg, corticosteroids, or plasma exchange. When someone remains disabled despite optimized doses of these proven therapies, clinicians face a challenging decision. A range of immunosuppressive drugs are used off-label in this setting, including azathioprine, mycophenolate mofetil, and cyclosporine, but none have been validated in large randomized trials. As one review put it, all of these agents require a delicate balance between risk, cost, and unknown likelihood of benefit, tailored to the individual patient’s circumstances.¹²

Small case series give a rough sense of what to expect. In one study of 13 patients receiving steroid-sparing immunosuppressive drugs, azathioprine was used most often and led to improvement in the majority of those who took it, while results with mycophenolate and cyclosporine were less encouraging.¹³ But case series are not trials, and the evidence base here is genuinely thin. Clinicians and patients are essentially making educated guesses, often cycling through agents over months or years.

Antibody Testing and Why It Changes Treatment Decisions

One of the more important developments in CIDP over the past decade has been the recognition that some patients harbor specific antibodies against proteins at the nodes of Ranvier, where the nerve’s insulating myelin sheath meets the exposed gap. Antibodies to neurofascin-155 (NF155), contactin-1, and contactin-associated protein 1 have been identified in a subset of patients, and when those antibodies belong to the IgG4 class, they define a clinically distinct group. These patients tend to be younger at onset, develop more severe neuropathy, and often have tremor and sensory ataxia.¹⁴

The practical importance is that these patients frequently do not respond to IVIg, the most common first-line therapy. Studies have found that NF155 IgG4-positive patients are often refractory to immunoglobulin treatment but may respond to rituximab, a drug that depletes B cells.¹⁵ This has been confirmed in multiple cohorts: patients with IgG4 nodal or paranodal antibodies have shown very high response rates to rituximab, enough that updated guidelines now classify these cases as a separate entity called autoimmune nodopathy rather than as a subtype of CIDP.¹⁶ The distinction matters enormously: a patient who might otherwise cycle through years of ineffective immunoglobulin therapy can be redirected toward rituximab much sooner if antibody testing is done early.

That said, these antibodies are uncommon, found in only a small fraction of patients diagnosed with CIDP. Case reports illustrate both the promise and the limits: in one refractory cohort, two patients tested positive for NF155 IgG4 antibodies, one responded to rituximab, and the other did not respond to any treatment tried.¹⁷ Antibody testing is informative but not a guarantee.

Emerging Therapies Targeting New Pathways

Standard CIDP treatments are blunt instruments: IVIg broadly modulates immunity, steroids suppress it widely, and plasma exchange removes everything from the blood indiscriminately. A new generation of therapies aims to be more precise. Two approaches have attracted the most attention.

The first involves FcRn inhibitors such as efgartigimod, drugs that accelerate the breakdown of IgG antibodies in the blood by blocking the receptor that normally recycles them. In a small Chinese case series, all five patients treated with efgartigimod responded, with four meeting predefined effectiveness criteria within eight weeks and an average drop in total IgG levels of about 43%.¹⁸ These are very early results, and larger trials are needed to establish how well this approach holds up over time. But the concept is appealing: rather than replacing missing immunoglobulin (as IVIg does) or broadly suppressing the immune system (as steroids do), FcRn inhibitors selectively reduce circulating antibodies, including the ones suspected of causing nerve damage.

The second involves the complement system, a cascade of proteins in the blood that amplifies immune attacks. Research increasingly implicates complement activation in the nerve damage seen in at least a subset of CIDP patients, and the failure of fingolimod, which targets T cells, has further shifted attention toward complement and antibody-driven pathways. Several complement inhibitors, each targeting a different step in the cascade, are in clinical development.¹⁹ If these pan out, they could offer targeted treatment for patients whose disease is driven by complement-mediated damage, potentially reducing the side effects and burden associated with current therapies.

Stem Cell Transplantation for Refractory Disease

For the small number of patients who do not respond to any available medical therapy, autologous hematopoietic stem cell transplantation (HSCT) is the most aggressive option on the table. The idea is to essentially reset the immune system: the patient’s own stem cells are collected, the existing immune system is wiped out with chemotherapy, and the stem cells are reinfused to rebuild it from scratch. More than 70 patients with refractory CIDP have undergone this procedure worldwide.²⁰

A systematic review and meta-analysis of the available data estimated that roughly 87% of transplanted patients responded, and about 81% achieved freedom from all immune-modulating or suppressive drugs afterward.²¹ In one detailed case series of 11 patients, disability scores improved within two to six months after transplantation, nerve conduction improved within about four months, and eight of 11 patients maintained drug-free remission at last follow-up. Three patients relapsed, one severely enough to require a second transplant.²²

The risks are real. Complications in that series included viral reactivation, hemorrhagic cystitis, and pancreatitis. This is not a therapy anyone takes lightly, and it is reserved for people who are significantly disabled despite exhausting other options. But for those patients, the response rates are striking compared to what conventional treatments typically offer in the refractory setting.

Exercise and Rehabilitation

Drug therapy addresses the immune attack driving CIDP, but it does not directly rebuild strength, endurance, or function that may have been lost during active disease. That is where structured exercise comes in. A study of CIDP patients found that an aerobic training program increased peak oxygen uptake by about 11%, while a resistance training program increased composite muscle strength by about 14%. Both results were statistically significant.²³ These gains matter for daily life: walking further, climbing stairs with less fatigue, maintaining grip strength for routine tasks.

What the evidence does not yet provide is guidance on managing two of CIDP’s most burdensome symptoms, fatigue and pain. A Cochrane overview found no trials at all addressing treatments for fatigue or pain specifically in CIDP.²⁴ In practice, clinicians borrow from the broader neuropathic pain literature, prescribing medications developed for diabetic neuropathy or postherpetic neuralgia, but the lack of CIDP-specific data is a genuine gap. Fatigue management tends to rely on general strategies like pacing, sleep optimization, and the exercise programs mentioned above.

The Cost Problem

CIDP treatment, especially IVIg, is expensive in a way that shapes real decisions. A U.S. claims-database analysis found that over a two-year period, mean CIDP therapy costs for patients on IVIg alone were roughly $120,000, compared to about $3,100 for patients on corticosteroids alone.²⁵ A separate case-control study estimated even higher two-year IVIg costs of about $165,000, compared to roughly $7,900 for corticosteroid-treated patients.²⁶

These numbers help explain why corticosteroids remain widely used despite their side effects, and why subcutaneous immunoglobulin, which can sometimes be dosed lower and administered without infusion center visits, has generated so much interest. They also underscore the importance of periodically testing whether a patient still needs immunoglobulin at all. Experts recommend attempting dose reduction or temporary withdrawal at regular intervals to identify patients who have entered remission and no longer require ongoing treatment. Without those attempts, some people end up on costly, burdensome infusions for years longer than necessary.

Why Early Diagnosis Matters

CIDP can be tricky to diagnose, and delays are common. The condition is uncommon enough that many clinicians encounter it rarely, and its symptoms, progressive or relapsing weakness and sensory changes in the limbs, overlap with other neuropathies. Research has shown that diagnostic delay matters beyond the obvious frustration: axonal loss in CIDP worsens with time, and accumulated axonal damage adversely affects treatment response.²⁷ In other words, the nerve damage that builds up while someone waits for a correct diagnosis is not fully reversible even once appropriate immunotherapy begins. This is one of the strongest arguments for referring any patient with progressive, symmetric weakness and sensory symptoms lasting more than eight weeks for specialized nerve conduction testing.

CIDP in Children

CIDP is rarer in children than in adults, and the disease tends to behave somewhat differently. In a pediatric cohort, about 90% of treated children received IVIg as their first immunotherapy, and roughly two-thirds of those responded well to it.²⁸ The course of childhood CIDP also differs: in that study, about 43% of children had a monophasic course, meaning the disease appeared once and did not relapse, while 57% had a relapsing-remitting pattern over a median follow-up of about three and a half years. A higher proportion of monophasic cases compared to adults may mean that some children can eventually stop treatment altogether, though ongoing monitoring is still needed. Steroid use in growing children raises additional concerns about growth and bone development, which makes IVIg an especially common first choice in this age group.

Monitoring Treatment and Attempting Withdrawal

One of the trickiest aspects of CIDP management is figuring out when to reduce or stop treatment. The disease often waxes and wanes, and many patients end up on long-term immunoglobulin or steroids without anyone testing whether they still need them. French experts in neuromuscular disease have emphasized the need for validated, reproducible monitoring tools applied at diagnosis, at treatment initiation, and throughout follow-up to guide these decisions on a case-by-case basis.²⁹

In practice, this typically means periodically reducing the immunoglobulin dose or stretching out the interval between infusions and watching closely for worsening. If a patient stays stable, the dose is reduced further. If they worsen, the dose is bumped back up. The goal is to find the minimum effective dose, or to discover that the patient can stop treatment entirely. Given that the PREDICT study’s long-term data showed that about a quarter of steroid-treated patients achieved sustained remission off treatment, the prospect is real. But the relapse rate among those who initially achieved remission, about 50%, is a reminder that withdrawal has to be done carefully and with close follow-up.